• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

BioGeneration Ventures

edit

BioGeneration Ventures is investing in the next generation of Life Sciences companies in the Netherlands.

BioGeneration Ventures invests in Dutch start-up and early stage life sciences companies.

The BioGeneration Ventures team is specialized in the evaluation and management of early stage companies. Their involvement goes beyond the financial investment. They work closely with scientists, academic institutions, entrepreneurs and industry experts to accelerate the development and to optimize the commercial potential of their portfolio company’s technologies. BioGeneration Ventures began operating in 2006 and the fund is backed by the Netherlands Genomics Initiative (NGI) and the Netherlands Organisation for Scientific Research (NWO) in combination with the holding company of Leiden University and ABN-AMRO Capital as lead private investors.

Recent Milestones

edit

• 
  BioGeneration Ventures invested in Lanthio Pharma. (11/28/12)
  Posted 11/28/12 at 7:37pm via finsmes.com
• 
  BioGeneration Ventures invested in arGEN-X. (2/11/10)
  Posted 2/15/10 at 6:25pm via onbiovc.com
• 
  BioGeneration Ventures invested in Medisse. (12/11/09)
  Posted 12/10/09 at 8:43pm
• 
  BioGeneration Ventures invested in arGEN-X. (9/10/09)
  Posted 9/14/09 at 6:17am via fiercebiotech.com
• 
  BioGeneration Ventures invested in FlexGen. (3/15/09)
  Posted 4/16/09 at 10:37pm via flexgen.nl

Investments

Videos

Sources

1. nwo.nl [edit]
2. Lanthio Pharma Raises €4.8M in First Close of Series A funding (finsmes.com) [edit]
3. arGEN-X, BV: Series A $4.5M (onbiovc.com) [edit]
4. Medisse Closes Funding From BioGeneration, Credit Agricole [edit]
5. arGEN-X gins $13.6M in new funds for mAB work (fiercebiotech.com) [edit]
6. FlexGen closes new round of financing (PDF) (flexgen.nl) [edit]